Trial Profile
A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer's Disease
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 12 Oct 2023
Price :
$35
*
At a glance
- Drugs Atabecestat (Primary) ; E 2814 (Primary) ; Florquinitau F18 (Primary) ; Gantenerumab (Primary) ; Lecanemab (Primary) ; Solanezumab (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Acronyms DIAN-TU; DIAN-TU-001; Tau NexGen Study
- 01 Jul 2023 Results (n=66) assessing Longitudinal head-to-head comparison of 11C-PiB and 18F-florbetapir PET in dominantly inherited Alzheimer's disease published in the European Journal of Nuclear Medicine and Molecular Imaging
- 30 Nov 2022 According to media release, data from this study presented at the Clinical Trials on Alzheimer's Disease (CTAD) conference
- 27 Nov 2022 Planned End Date changed from 1 Jul 2022 to 1 Oct 2027.